Dova Pharmaceuticals Inc (NASDAQ:DOVA) – Analysts at Leerink Swann upped their FY2021 earnings per share estimates for Dova Pharmaceuticals in a note issued to investors on Friday. Leerink Swann analyst G. Porges now forecasts that the company will post earnings per share of $4.97 for the year, up from their previous forecast of $4.96.
DOVA has been the topic of a number of other research reports. BidaskClub raised shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Zacks Investment Research cut shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, Jefferies Group increased their price objective on shares of Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, November 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Dova Pharmaceuticals has an average rating of “Buy” and a consensus price target of $32.75.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Thursday, February 15th. The company reported ($0.36) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.36). During the same quarter in the prior year, the firm posted ($0.44) EPS.
Several hedge funds have recently added to or reduced their stakes in DOVA. The Manufacturers Life Insurance Company boosted its position in shares of Dova Pharmaceuticals by 702.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock worth $137,000 after purchasing an additional 4,163 shares in the last quarter. California State Teachers Retirement System bought a new position in shares of Dova Pharmaceuticals during the 3rd quarter worth about $202,000. Schwab Charles Investment Management Inc. bought a new position in shares of Dova Pharmaceuticals during the 3rd quarter worth about $241,000. Virtus Fund Advisers LLC bought a new position in shares of Dova Pharmaceuticals during the 4th quarter worth about $318,000. Finally, Deutsche Bank AG boosted its position in shares of Dova Pharmaceuticals by 139.2% during the 4th quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock worth $337,000 after purchasing an additional 6,836 shares in the last quarter. 26.93% of the stock is currently owned by institutional investors.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.